Stock 2192 MEDLIVE TECHNOLOGY CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Medlive Technology Co., Ltd.

Equities

2192

KYG5961B1041

Delayed Hong Kong S.E.
Other stock markets
 11:33:26 2024-04-29 pm EDT 		5-day change 1st Jan Change
8.08 HKD -0.98% Intraday chart for Medlive Technology Co., Ltd. +2.67% -4.72%
Apr. 29 Medlive Technology More than Doubles Profit in 2023 MT
Mar. 25 Medlive Technology Co., Ltd. Proposes Final Dividend for the Year Ended December 31, 2023, Payable on June 24, 2024 CI

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

  • The prospective high growth for the next fiscal years is among the main assets of the company
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • For several months, analysts have been revising their EPS estimates roughly upwards.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • The opinion of analysts covering the stock has improved over the past four months.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.
  • Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

Weaknesses

  • The company benefits from high valuations in earnings multiples.
  • The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.

Ratings chart - Surperformance

Sector: Advertising & Marketing

1st Jan change Capi. Investor Rating ESG Refinitiv
MEDLIVE TECHNOLOGY CO., LTD. Stock Medlive Technology Co., Ltd.
-4.72% 757M -
PUBLICIS GROUPE SA Stock Publicis Groupe SA
+23.99% 27.88B
A-
OMNICOM GROUP., INC. Stock Omnicom Group., Inc.
+10.84% 18.78B
B+
FOCUS MEDIA INFORMATION TECHNOLOGY CO., LTD. Stock Focus Media Information Technology Co., Ltd.
+10.92% 13.65B
C-
THE INTERPUBLIC GROUP OF COMPANIES, INC. Stock The Interpublic Group of Companies, Inc.
-3.71% 11.88B
B
WPP PLC Stock WPP plc
+8.53% 10.86B
A-
JCDECAUX SE Stock JCDECAUX SE
+9.23% 4.45B
A-
PEOPLE.CN CO., LTD Stock People.cn CO., LTD
-9.36% 3.74B -
C-
HAKUHODO DY HOLDINGS INC Stock Hakuhodo DY Holdings Inc
+35.86% 3.4B
C
CYBERAGENT, INC. Stock CyberAgent, Inc.
+12.74% 3.31B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 2192 Stock
  4. Ratings Medlive Technology Co., Ltd.